Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 12/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 12/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 12/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 12/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | SQOR | Q9Y6N5 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2645113 | 0.86 | GABRG2 (0.46) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2645223 | 0.85 | GABRG2 (0.46) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2645638 | 0.84 | GABRG2 (0.47) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2644368 | 0.84 | GABRG2 (0.45) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2645249 | 0.84 | GABRG2 (0.46) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2644133 | 0.82 | GABRG2 (0.48) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2644597 | 0.81 | GABRG2 (0.46) | GABRG2GABRB3GABRA5GABRA3ADORA1 | |
| SCHEMBL2645305 | 0.78 | TRPA1 (0.43) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2644499 | 0.77 | GABRG2 (0.59) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2644598 | 0.77 | GABRG2 (0.48) | GABRG2GABRB3GABRA5GABRA3GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969716-B2 | 5-phenyl[1,2,4]triazines as ligands for GABA-A α2/α3 receptors for treating anxiety or depression | MERCK SHARP & DOHME LTD. | 2005-11-29 | — | — | US | claimed |
| US-20040192692-A1 | 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression | MERCK SHARP & DOHME, LTD. (GB) | 2004-09-30 | — | — | US | claimed |
| US-6969716-B2 | 5-phenyl[1,2,4]triazines as ligands for GABA-A α2/α3 receptors for treating anxiety or depression | MERCK SHARP & DOHME LTD. | 2005-11-29 | — | — | US | disclosed |
| US-20040192692-A1 | 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression | MERCK SHARP & DOHME, LTD. (GB) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192692-A1 | 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression | GABRA1, GABRA5, GABRA2 | GABRG2 15/4885GABRB3 10/4885GABRA5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.